PDF(Pubmed)
Abstract：
UNASSIGNED: Tixagevimab-cilgavimab is a combination of 2 mAbs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In December 2021, the Food and Drug Administration issued Emergency Use Authorization for intramuscular injection of tixagevimab-cilgavimab for prophylaxis against SARS-CoV-2 in immunocompromised patients. Shortly thereafter, our clinic distributed tixagevimab-cilgavimab to patients with common variable immunodeficiency.
UNASSIGNED: We sought to evaluate the effectiveness and tolerability of tixagevimab-cilgavimab in a common variable immunodeficiency clinic.
UNASSIGNED: A retrospective chart review from February 1, 2022, to August 1, 2022, of 47 patients with common variable immunodeficiency who were offered tixagevimab-cilgavimab was carried out. Comparative outcomes of treatment and nontreatment groups examined the occurrence of SARS-CoV-2 infection, severity of SARS-CoV-2 infection, and other non-SARS-CoV-2 infections.
UNASSIGNED: Seventy percent of the patients were female; mean age was 49 years. Twenty-three patients received tixagevimab-cilgavimab, and 24 did not receive prophylaxis. In the tixagevimab-cilgavimab group, all were vaccinated for SARS-CoV-2 and 22 were receiving immunoglobulin replacement. One patient was infected with SARS-CoV-2, no patients required emergency care, and 7 patients had non-SARS-CoV-2 infection. In the cohort that did not receive prophylaxis, 21 were vaccinated, and all received immunoglobulin replacement. Two patients tested positive for SARS-CoV-2, 1 patient required emergency care due to SARS-CoV-2 disease severity, and 4 patients had a non-SARS-CoV-2 infection. None of the results showed statistical significance.
UNASSIGNED: Although there is evidence that tixagevimab-cilgavimab can be protective against SARS-CoV-2 in immunocompromised individuals, our data suggest that this benefit may be blunted in patients with common variable immunodeficiency on immunoglobulin replacement. The additional benefit of tixagevimab-cilgavimab in immunocompromised patients already receiving replacement therapy requires further exploration.
UNASSIGNED: We sought to evaluate the effectiveness and tolerability of tixagevimab-cilgavimab in a common variable immunodeficiency clinic.
UNASSIGNED: A retrospective chart review from February 1, 2022, to August 1, 2022, of 47 patients with common variable immunodeficiency who were offered tixagevimab-cilgavimab was carried out. Comparative outcomes of treatment and nontreatment groups examined the occurrence of SARS-CoV-2 infection, severity of SARS-CoV-2 infection, and other non-SARS-CoV-2 infections.
UNASSIGNED: Seventy percent of the patients were female; mean age was 49 years. Twenty-three patients received tixagevimab-cilgavimab, and 24 did not receive prophylaxis. In the tixagevimab-cilgavimab group, all were vaccinated for SARS-CoV-2 and 22 were receiving immunoglobulin replacement. One patient was infected with SARS-CoV-2, no patients required emergency care, and 7 patients had non-SARS-CoV-2 infection. In the cohort that did not receive prophylaxis, 21 were vaccinated, and all received immunoglobulin replacement. Two patients tested positive for SARS-CoV-2, 1 patient required emergency care due to SARS-CoV-2 disease severity, and 4 patients had a non-SARS-CoV-2 infection. None of the results showed statistical significance.
UNASSIGNED: Although there is evidence that tixagevimab-cilgavimab can be protective against SARS-CoV-2 in immunocompromised individuals, our data suggest that this benefit may be blunted in patients with common variable immunodeficiency on immunoglobulin replacement. The additional benefit of tixagevimab-cilgavimab in immunocompromised patients already receiving replacement therapy requires further exploration.
摘要：
■Tixagevimab-cilgavimab是2种针对严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）的单克隆抗体的组合。2021年12月，美国食品和药物管理局发布了肌内注射替沙格维单抗-西加维单抗的紧急使用许可，以预防免疫功能低下的患者的SARS-CoV-2。此后不久,我们的诊所为常见的可变免疫缺陷患者分配了tixagevimab-cilgavimab。
■我们试图评估替沙格维单抗-西加维单抗在常见的可变免疫缺陷诊所中的有效性和耐受性。
■从2022年2月1日至2022年8月1日，对47名接受替沙格维单抗-西加维单抗治疗的常见变异型免疫缺陷患者进行了回顾性图表审查。治疗组和非治疗组的比较结果检查了SARS-CoV-2感染的发生，SARS-CoV-2感染的严重程度，和其他非SARS-CoV-2感染。
■70%的患者为女性；平均年龄为49岁。23名患者接受了替沙格维单抗-西加维单抗，24人没有接受预防。在tixagevimab-cilgavimab组中,所有人都接种了SARS-CoV-2疫苗,22人接受了免疫球蛋白替代治疗.一名患者感染了SARS-CoV-2，没有患者需要紧急护理，7例非SARS-CoV-2感染。在没有接受预防的队列中，21人接种了疫苗，所有人都接受了免疫球蛋白替代治疗.两名患者SARS-CoV-2检测呈阳性，一名患者由于SARS-CoV-2疾病的严重程度而需要紧急护理，4例患者非SARS-CoV-2感染。结果均无统计学意义。
■尽管有证据表明tixagevimab-cilgavimab可以在免疫功能低下的个体中预防SARS-CoV-2，我们的数据表明,在免疫球蛋白替代治疗中,这种获益可能会减弱.在已经接受替代疗法的免疫功能低下的患者中，tixagevimab-cilgavimab的额外益处需要进一步探索。
■我们试图评估替沙格维单抗-西加维单抗在常见的可变免疫缺陷诊所中的有效性和耐受性。
■从2022年2月1日至2022年8月1日，对47名接受替沙格维单抗-西加维单抗治疗的常见变异型免疫缺陷患者进行了回顾性图表审查。治疗组和非治疗组的比较结果检查了SARS-CoV-2感染的发生，SARS-CoV-2感染的严重程度，和其他非SARS-CoV-2感染。
■70%的患者为女性；平均年龄为49岁。23名患者接受了替沙格维单抗-西加维单抗，24人没有接受预防。在tixagevimab-cilgavimab组中,所有人都接种了SARS-CoV-2疫苗,22人接受了免疫球蛋白替代治疗.一名患者感染了SARS-CoV-2，没有患者需要紧急护理，7例非SARS-CoV-2感染。在没有接受预防的队列中，21人接种了疫苗，所有人都接受了免疫球蛋白替代治疗.两名患者SARS-CoV-2检测呈阳性，一名患者由于SARS-CoV-2疾病的严重程度而需要紧急护理，4例患者非SARS-CoV-2感染。结果均无统计学意义。
■尽管有证据表明tixagevimab-cilgavimab可以在免疫功能低下的个体中预防SARS-CoV-2，我们的数据表明,在免疫球蛋白替代治疗中,这种获益可能会减弱.在已经接受替代疗法的免疫功能低下的患者中，tixagevimab-cilgavimab的额外益处需要进一步探索。
